Tetracycline regulated systems in functional oncogenomics.
| dc.contributor.author | Welman, Arkadiusz | |
| dc.contributor.author | Barraclough, Jane | |
| dc.contributor.author | Dive, Caroline | |
| dc.date.accessioned | 2013-06-14T15:16:22Z | |
| dc.date.available | 2013-06-14T15:16:22Z | |
| dc.date.issued | 2007 | |
| dc.identifier.citation | Tetracycline regulated systems in functional oncogenomics. 2007, 2:17-33 Transl Oncogenomics | en_GB |
| dc.identifier.issn | 1177-2727 | |
| dc.identifier.pmid | 23645981 | |
| dc.identifier.uri | http://hdl.handle.net/10541/293992 | |
| dc.description.abstract | The increasing number of proteomic and DNA-microarray studies is continually providing a steady acquisition of data on the molecular abnormalities associated with human tumors. Rapid translation of this accumulating biological information into better diagnostics and more effective cancer therapeutics in the clinic depends on the use of robust function-testing strategies. Such strategies should allow identification of molecular lesions that are essential for the maintenance of the transformed phenotype and enable validation of potential drug-targets. The tetracycline regulated gene expression/ suppression systems (Tet-systems) developed and optimized by bioengineers over recent years seem to be very well suited for the function-testing purposes in cancer research. We review the history and latest improvements in Tet-technology in the context of functional oncogenomics. | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Translational oncogenomics | en_GB |
| dc.title | Tetracycline regulated systems in functional oncogenomics. | en |
| dc.type | Article | en |
| dc.contributor.department | Cancer Research U.K., Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester M20 4BX, United Kingdom. | en_GB |
| dc.identifier.journal | Translational Oncogenomics | en_GB |
| html.description.abstract | The increasing number of proteomic and DNA-microarray studies is continually providing a steady acquisition of data on the molecular abnormalities associated with human tumors. Rapid translation of this accumulating biological information into better diagnostics and more effective cancer therapeutics in the clinic depends on the use of robust function-testing strategies. Such strategies should allow identification of molecular lesions that are essential for the maintenance of the transformed phenotype and enable validation of potential drug-targets. The tetracycline regulated gene expression/ suppression systems (Tet-systems) developed and optimized by bioengineers over recent years seem to be very well suited for the function-testing purposes in cancer research. We review the history and latest improvements in Tet-technology in the context of functional oncogenomics. |